TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06444243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niacin
Description: A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacin helps some enzymes work properly and helps skin, nerves, and the digestive tract stay healthy. Niacin is found in many plant and animal products.~Niacin will be used at a concentration of 250mg as an active control.
Study: NCT05385042

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sangobion and Thiamine Hydrochloride
Description: Prophylactic dietary supplements: 1 capsule of Sangobion + separate Thiamine Hydrochloride tablet 100mg per day for 12 weeks.~Then non-anaemic pregnant women will continue with prophylactic nutritional supplements until delivery.
Study: NCT06491212

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Determination of Foot Deformity Level
Description: One of the methods used in our study to determine the presence and degree of pes planus is the navicular drop test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of Foot Deformity Level
Description: One of the methods used in our study to determine the presence and degree of pes planus is the navicular drop test.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Foot Function Index
Description: Evaluation of Foot Function
Study: NCT05385042

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sangobion, Thiamine hydrochloride and Vitamin B12
Description: Treatment dietary supplements: 3 capsules of Sangobion + separate Thiamine Hydrochloride tablet 100mg, Vit B12 100mcg per day for 12 weeks.~If experience a therapeutic increase of 3% Haematocrit within 28 days (responders), they will continue with prophylactic nutritional supplements until delivery.~If no affect in Haematocrit level within 28 days (non-responders; defined by trimester of diagnosis), they will be investigated for their serum ferritin and if this is low (\<15ng/mL) intravenous (iv) iron supplement (Venofer®) will be provided. The dose will be calculated for the individual concerned (required iron dose (mg) = (2.4 x (target Hb of 11g/dL (Ht 33%) x pre-pregnancy weight (kg) +1000mg for replenishment of stores). Doses will be administered by slow iv infusion 200 mg per dose (maximum of 3 doses per week).~Following treatment they will continue with prophylactic nutritional supplements.
Study: NCT05216406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-HTP
Description: CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
Study: NCT06491212

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Foot Function Index
Description: Evaluation of Foot Function

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: UFAA-International Physical Activity Questionnaire
Description: To determination of physical activity level.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UFAA-International Physical Activity Questionnaire
Description: To determination of physical activity level.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm ultrasound measurements
Description: Rehabilitative ultrasound imaging is a method frequently used by physiotherapists to assess muscle function.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diaphragm ultrasound measurements
Description: Rehabilitative ultrasound imaging is a method frequently used by physiotherapists to assess muscle function.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NeuruCom Balance Master Balnce and Performans Test
Description: Balance master will be used for postural stability, static and dynamic balance measurements.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NeuruCom Balance Master Balnce and Performans Test
Description: Balance master will be used for postural stability, static and dynamic balance measurements.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Plantar Pressure Assessment
Description: When assessing plantar pressure, postural control will be evaluated statically or dynamically, through examination of the behavior of the center of plantar pressure (COP).
Study: NCT05216406

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin capsule
Study: NCT06491212

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plantar Pressure Assessment
Description: When assessing plantar pressure, postural control will be evaluated statically or dynamically, through examination of the behavior of the center of plantar pressure (COP).
Study: NCT04704739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205 film-coated tablets
Description: Single oral dose of GLPG1205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1205 solution for infusion
Description: A 15-minute IV infusion of \[14C\]-GLPG1205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205 capsules
Description: Single oral dose of GLPG1205 as solid formulation
Study: NCT05656846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseNmore ES™
Description: The patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ultrasound
Description: These patients will not receive the additional intervention and will use the Standard Ultrasound. A population of patients between 12 and 22 weeks of gestation with history of recurrent pregnancy losses who will be subjected to routine antenatal care as per clinic protocol. These patients will not receive the additional intervention.
Study: NCT06261996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fospropofol
Description: Fospropofol is administered after admission to the room at a pumping rate of 1 mg/kg/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fospropofol
Description: Fospropofol is administered after admission to the room at a pumping rate of 1 mg/kg/h.
Study: NCT05952089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Specified dose on specified days
Study: NCT05125562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ExoFlo
Description: Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation A
Description: Oral administration of VH4004280 Formulation A in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation A
Description: Oral administration of VH4004280 Formulation A in fasted or fed conditions.
Study: NCT05433194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABO1009-DP
Description: Vaccine
Study: NCT05628584

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High FODMAP diet with metformin
Description: Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation A
Description: Oral administration of VH4004280 Formulation A in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation A
Description: Oral administration of VH4004280 Formulation A in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation A
Description: Oral administration of VH4004280 Formulation A in fasted or fed conditions.
Study: NCT05576844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week interpersonal and social rhythm intervention
Description: The development of the intervention strategies are based on social rhythm theory, interpersonal and social rhythm therapy, and previous research results, and the intervention aims to improve sleep by stabilizing participants' social rhythm and increasing the amount of interpersonal communication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Control group participants received usual care, including daily disease management and routine drug guidance.
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation A
Description: Oral administration of VH4004280 Formulation A in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation B
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.
Study: NCT05628584

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Low FODMAP diet with metformin
Description: Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
Study: NCT06273891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Erythromycin 250 mg IV every 6 hours for 48 hours, followed by 250 mg PO or 333 mg PO every 8 hours for 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 1 gm PO once or 500 mg PO followed by 250 mg PO daily for a total of 5 days~in addition to Ampicillin 2 gm IV every 6 hours for 2 days followed by Amoxicillin 250 mg PO every 8 hours for 5 days
Study: NCT05802264

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ABCI
Description: Subjects will receive ABCI via oral inhalation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ABCI
Description: Subjects will receive ABCI via oral inhalation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ABCI
Description: Subjects will receive ABCI via oral inhalation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive ABCI via oral inhalation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive ABCI via oral inhalation
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation B
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation B
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation B
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.
Study: NCT05286762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 12.5 mg (titration only)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 12.5 mg (titration only)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg
Study: NCT05957497

Intervention type: BIOLOGICAL
Intervention: Biological samples transport and analysis
Description: Biological samples transport and analysis
Study: NCT05286762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 12.5 mg (titration only)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation B
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation B
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation B
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation B
Description: Oral administration of VH4004280 Formulation B in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation C
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation C
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation C
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation C
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.
Study: NCT05286762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation C
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation C
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.
Study: NCT05286762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)
Description: Subjects will be randomized at Visit 2 to CTx-1301 to 12.5mg, then week 1 to 18.75 mg, then week 2 to 25 mg, then week 3 to 37.5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized at Visit 2 to Placebo
Study: NCT06392633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spastic hand sugery
Description: Deformity correction can be performed with single event multilevel surgery, using a combination of soft tissue releases and lengthening, tendon transfers and joint stabilization procedures. In addition, selective and supraselective neurectomies can also be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Description: Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
Study: NCT04803630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Description: Undergo thermal therapy
Study: NCT06199648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based documentation and advice
Description: Caregivers will be supported with a web-based documentation and advice system for home care for elderly people
Study: NCT05243355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab and Chemotherapy and Recombinant Human Endostatin
Description: Envafolimab: 300 mg，D1，Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total.~Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total.
Study: NCT05916820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tanzberger Exercises
Description: It consists of patients who will receive Tanzberger exercise 3 sessions per week for 4 weeks. e.g. Rolling on the ball forward, Back to back sitting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: It consists of patients who will pelvic floor muscles exercise 3 sessions per week for 4 weeks. e.g. Assisted heel drop, Bridge, Dead Bug, Bird DOG
Study: NCT04063410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiography
Description: Undergo standard of care CTA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Based Angiogram
Description: Undergo pPCA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05296850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Release
Description: Individuals are placed in the prone position with their knees extended. The calcaneus is kept in eversion while maintaining talocrural dorsiflexion. As the toes are stretched in dorsiflexion, the therapist slides the big toe distally and proximally along the plantar fascia and flexor hallucis longus. Soft tissue mobilization depth will be applied according to the patient's tolerance and reactivity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: In the first technique, an I tape will be applied on the plantar surface of the foot from the metatarsal heads to the popliteal fossa. First, the middle of the band is attached to the inferior of the calcaneus as the first anchor, then the ankle is dorsiflexed and the upper part of the band is applied with 15-25% tension until the popliteal fossa. The plantar fascia is placed in a stretched position by dorsiflexing the ankle and fingers, and the ends of the tape, which is divided into 4 parts, are applied separately to the metatarsal heads with 75-100% tension. In the second technique, the application is made with an I tape. The initial anchor starts from the dorsal aspect of the 5th metatarsal on the lateral aspect of the foot. Then, the tape passes to the medial side of the foot with 75-100% tension and is adhered to the medial side of the foot and ankle over the navicular. The end anchor is applied without tension.
Study: NCT06168318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation C
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation C
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation D
Description: Oral administration of VH4004280 Formulation D in fasted or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280 Formulation E
Description: Oral administration of VH4004280 Formulation E in fasted or fed conditions.
Study: NCT05082714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: tocilizumab 8mg/kg single infusion (a second infusion within 48 hours can be applied upon clinician's discretion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: The baricitinib intervention consists of baricitinib at a dose of 4 mg/day (given daily for up to 14 days or until discharge from hospital, whichever occurred first); however, 2 mg/day will be given if the patient has a baseline eGFR of 30 to less than 60 mL/min/1·73 m2
Study: NCT05390814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: \[18F\]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
Study: NCT06028984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention app
Description: An app-based intervention for depression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control app
Description: An app with non-therapeutic content